RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing
RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine.
FREDERICK, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, today announces the signing of a strategic collaboration with Sartorius, a leading international partner of life science research and the biopharmaceutical industry. The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly reduce process development efforts, industrialize the supply chain and accelerate the development and commercialization of groundbreaking cell-based regenerative cures.
RoosterBio and Sartorius will create a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems, alongside Sartorius’s single use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing. Cell expansion will be rapidly optimized using Sartorius’s benchtop Ambr® system and MODDE® design of experiment software allowing the technical team to compare cultures in identically sized, multi-parallel bioreactors to gain process information and optimized conditions in a short timeline. Sartorius’s scalable Biostat STR® production bioreactors will then be used to scale up to 50L as part of this collaboration, with the system benefitting from scalability to 2000L. Sartorius equipment will also be leveraged to develop post-harvest processing methods with the kSep® system as well as process and quality analytics. This joint effort will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that can be implemented for rapid scale up of manufacturing processes, allowing product developers to significantly speed up their development timelines.
“Taking hMSC manufacturing to the thousand-liter scale is critical in meeting product dose requirements in commercial manufacturing,” said RoosterBio CEO Margot Connor. “For truly robust and standardized production in the field, a highly controlled manufacturing strategy is needed, with the implementation of automation, process monitoring and control to increase batch scale, consistency and efficiency. This collaboration is well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying foundation for true commercial scale manufacturing.”
“With the combination of technologies and tools of RoosterBio and Sartorius we support our customers to develop stem cell and therapies faster, better and more cost-efficient. Scalability is key in commercial manufacturing and this cooperation will help to meet the requirements of our customers even better,” said Hugo de Wit, Head of Advanced Therapies at Sartorius.
Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field. Visit www.roosterbio.com.
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
RoosterBio: Carrie Zhang, Director of Marketing
Sartorius: Andre Hofmann, Head of Public Relations
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Equinor ASA: Early Warning Press Release20.1.2021 12:49:07 CET | Press release
Stavanger, Rogaland, Norway, January 20, 2021 – Equinor ASA ("Equinor") (OSE: EQNR, NYSE: EQNR) announces that on January 19, 2021 it disposed of its beneficial ownership of an aggregate of 100,000,000 common shares ("Common Shares") of Athabasca Oil Corporation ("Athabasca"), at a price of C$0.18 per Common Shares, for aggregate gross proceeds of C$18,000,000 (the "Transaction"), through the facilities of the Toronto Stock Exchange on a block trade basis. Immediately prior to the Transaction, Equinor beneficially owned and controlled a total of 100,000,000 Common Shares of Athabasca, representing approximately 18.8% of the issued and outstanding Common Shares of Athabasca. Immediately following the Transaction, Equinor no longer has beneficial ownership and control over any of the issued and outstanding Common Shares of Athabasca. As a result of the Transaction, Equinor's beneficial ownership of Common Shares of Athabasca has decreased to less than 10% of the issued and outstanding Co
RESULT RIKSBANK PURCHASES OF CORPORATE BONDS20.1.2021 11:30:00 CET | Press release
AuctionResult of auctionAuction date2021-01-20NameAKELIUS FASTIGHETER ABIsinXS1692931980 Coupon1.125Maturity2021-10-04Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln30Volume bought, SEK mln30Number of bids1Number of accepted bids1Average yield0.10 %Lowest accepted yield0.10 %Highest yield0.10 %Accepted at lowest yield, %100.00 AuctionResult of auctionAuction date2021-01-20NameAKELIUS FASTIGHETER ABIsinXS1889043359Coupon1.875Maturity2023-10-03Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln0Volume bought, SEK mln0Number of bids0Number of accepted bids0Average yieldn/aLowest accepted yieldn/aHighest yieldn/aAccepted at lowest yield, %n/a AuctionResult of auctionAuction date2021-01-20NameFASTIGHETS AB BALDERIsinSE0013359726Coupon1.363Maturity2022-07-01Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln0Volume bought, SEK mln0Number of bids0Number of accepted bids0Average yieldn/aLowest accepted yieldn/aHighest yieldn/aAccepted at lowest yield, %n/a AuctionResult of
Change in Sampo Group Executive Committee20.1.2021 11:00:00 CET | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 20 January 2021 at 12:00 pm Change in Sampo Group Executive Committee Due to an internal organizational change in Sampo’s subsidiary If P&C, Ivar Martinsen has today left his position as Head of BA Commercial and consequently is, by a decision made by Sampo Board of Directors, no longer a member of Sampo Group Executive Committee. As of today, Ivar Martinsen has taken up a new position as Senior Advisor in If. In his new role, Martinsen will support the CEOs of If and Sampo in matters related to P&C business. Martinsen was Head of BA Commercial since 2003 and member of Group Executive Committee since 2005. Klas Svensson has been appointed as new Head of BA Commercial. Svensson was previously Head of Digital Sales & Customer Experience in BA Private. He’s been working in different positions in BA Private in Denmark and Sweden since 2012. SAMPO PLC Investor Relations and Group Communications For further information, please contact: Jarmo Salonen Head of I
Nokia and Mobily pilot world’s first 4G and 5G Fixed Wireless Access network slicing20.1.2021 10:30:00 CET | Press release
Press Release Nokia and Mobily pilot world’s first 4G and 5G Fixed Wireless Access network slicing First-ever network slicing trial on a live commercial network showcases fixed wireless access (FWA) slicing use case for the first time The pilot will enable new services and high-quality customer experience to consumers and enterprises in Saudi ArabiaNokia is first vendor to deploy 4G and 5G network slicing in live multi-vendor network across all domains, including access, transport and core 20 January 2021 Espoo, Finland – Nokia today announced that it has successfully piloted 4G and 5G fixed wireless access (FWA) network slicing with Saudi Arabian telecommunications services provider, Mobily on their live commercial network – the first sliced FWA deployment in the world. The ongoing pilot, which took place in the capital city of Riyadh, occurred in a multi-vendor environment and included sliced access, transport and core networks with management and assurance capabilities. The solution
Result of Riksbank´s purchases of Commercial Paper20.1.2021 10:00:00 CET | Press release
AuctionAuction resultsAuction date2021-01-20Settlement date2021-01-22Credit rating class1Term3mFixed purchase rate, %0.3Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-01-20Settlement date2021-01-22Credit rating class1Term6mFixed purchase rate, %0.4Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-01-20Settlement date2021-01-22Credit rating class2Term3mFixed purchase rate, %0.6Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-01-20Settlement date2021-01-22Credit rating class2Term6mFixed purchase rate, %0.7Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0
Kinneviks vice ordförande Henrik Poulsen ställer inte upp för omval20.1.2021 09:30:00 CET | Pressemelding
Kinnevik AB (publ) (“Kinnevik”) meddelade idag att styrelsens vice ordförande Henrik Poulsen har meddelat valberedningen att han inte ställer upp för omval vid årsstämman 2021. Anders Oscarsson, ordförande i valberedningen, kommenterade: ”Å aktieägarnas vägnar vill jag framföra vårt tack till Henrik Poulsen för hans värdefulla arbete i Kinneviks styrelse. Valberedningen ser fram emot att presentera sitt fullständiga förslag till ny styrelse i god tid innan årsstämman.” För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email firstname.lastname@example.org Kinnevik är ett sektorfokuserat investmentbolag som brinner för entreprenörskap. Vårt syfte är att förbättra människors liv genom att erbjuda fler och bättre valmöjligheter. Tillsammans med drivna grundare och företagsledare bygger vi bolag som genom digitalisering och teknisk innovation tillgodoser väsentliga vardagsbehov hos konsumenten. Som aktiva ägare tror v
Kinnevik’s Deputy Chairman Henrik Poulsen will not be available for re-election20.1.2021 09:30:00 CET | Press release
Kinnevik AB (publ) ("Kinnevik”) today announced that the Deputy Chairman of the Board of Directors, Henrik Poulsen, has informed the Nomination Committee that he will not be available for re-election at the Annual General Meeting in 2021. The Chairman of the Nomination Committee, Anders Oscarsson, commented: “On behalf of the shareholders I would like to thank Henrik for his dedicated work in the Kinnevik board. The nomination committee looks forward to presenting its full proposal of the new board well ahead of the Annual General Meeting.” For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Investor Relations Phone +46 (0)70 762 00 50 Email email@example.com Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to make people’s lives better by providing more and better choice. In partnership with talented founders and management teams we build challenger businesses that use disruptive technology to address mat